Penetration and accumulation of moxifloxacin in uterine tissue

International Journal of Gynecology and Obstetrics

Volumn 102, Issue 2, 2008, Pages 132-136

  Stass, Heino ^a   Kubitza, Dagmar ^a   Aydeniz, Baybur ^b   Wallwiener, Deithelm ^b   Halabi, Atef ^c   Gleiter, Christoph ^d  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c CRS Clinical Research Services Kiel GmbH   (Germany)

^d CenTrial GmbH   (Germany)

Author keywords

Moxifloxacin; Pelvic inflammatory disease; Pharmacokinetics; Uterine tissue

Indexed keywords

MOXIFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC THERAPY; APNEA; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; HUMAN; MALAISE; METRITIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 46749100512     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2008.02.020     Document Type: Article

References (27)

1. Barrett S., and Taylor C. A review on pelvic inflammatory disease. Int J STD AIDS 16 (2005) 715-721
2. Ross J. Pelvic inflammatory disease. BMJ 322 (2001) 658-659
3. Royal College of Obstetricians and Gynaecologists. Management of acute pelvic inflammatory disease. Guideline vol. 32 (2003), RCOG Press, London UK 9. http://www.rcog.org.uk/resources/Public/pdf/Pelvic_Inflamatory_Disease_No32.pdf www.rcog.org.uk/resources/Public/pdf/Pelvic_Inflamatory_Disease_No32.pdf
4. Hillis S.D., Joesoef R., Marchbanks P.A., Wasserheit J.N., Cates W., and Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 168 (1993) 1503-1509
5. Hillis S.D., Owens L.M., Marchbanks P.A., Amsterdam L.F., and MacKenzie W.R. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 176 (1997) 103-107
6. Ross J.D., Cronjé H.S., Paszkowski T., Rakoczi I., Vildaite D., Kureishi A., et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect 82 (2006) 446-451
7. Dunbar-Jacob J., Sereika S.M., Foley S.M., Bass D.C., and Ness R.B. Adherence to oral therapies in pelvic inflammatory disease. J Womens Health 13 (2004) 285-291
8. Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., and Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 41 (1997) 101-106
9. Donati M., Rodriguez Fermepin M., Olmo A., D'Apote L., and Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline, and azithromycin against Chlamydia spp. J Antimicrob Chemother 43 (1999) 825-827
10. Aldridge K.E., and Ashcraft D.S. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, against clinically important anaerobes. Antimicrob Agents Chemother 41 (1997) 709-711
11. Stass H., and Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 702 (1997) 163-174
12. Stass H., and Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 43 (1999) S83-S90 (suppl B)
13. Wirtz M., Kleeff J., Swoboda S., Halaceli I., Geiss H.K., Hoppe-Tichy T., et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 53 (2004) 875-877
14. Stass H., Rink A.D., Delesen H., Kubitza D., and Vestweber K.-H. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 58 (2006) 693-696
15. Müller M., Stass H., Brunner M., Moller J.G., Lackner E., and Eichler H.G. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 43 (1999) 2345-2349
16. Williams W.L., Northwood J., and Morrissey I. Activity of moxifloxacin and comparators against recent isolates of Chlamydia trachomatis. Presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (April 1-4 2006), France, Nice 1298 Poster
17. Cevenini R., Donati M., Pignanelli S., Accardo S., Cavrini F., and Mazzeo C. In vitro antichlamydial activity of moxifloxacin versus a range of antimicrobial agents. Presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (April 1-4 2006), Nice, France 715 Poster
18. Rennie R.P., Turnbull L., Brosnikoff C., Harris M., Tyrrell G., Hoang L., et al. Susceptibility of recent Neisseria gonorrhoeae strains from Canada to moxifloxacin, ciprofloxacin and cefixime. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (September 17-20 2007), Illinois, USA, Chicago E2086 Poster
19. Alcalá L., Cercenado E., Garcia-Garrote F., and Bouza E. In vitro activity of the new quinolone moxifloxacin (BAY 12-8039) against resistant gram-positive clinical isolates. Diagn Microbiol Infect Dis 33 (1999) 27-31
20. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40 (1997) 639-651
21. Bébéar C.M., Renaudin H., Boudjadja A., and Bébéar C. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob Agents Chemother 42 (1998) 703-704
22. Bébéar C.M., Renaudin H., Planty C., Pereyre S., and Bébéar C. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp. and Mycoplasma hominis. Poster presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (April 1-4 2006), Nice, France 725 Poster
23. Bébéar C.M., Renaudin H., Jensen J.S., and Bébéar C. Activity of moxifloxacin against Mycoplasma genitalium. Poster presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (April 1-4 2006), Poster, Nice, France 726 Poster
24. Alexander C.J., Goldstein E.J., Citron D.M., and DeCherney A.H. Review of the comparative in vitro susceptibilities of lower female genital tract pathogens to older and newer fluoroquinolones. Anaerobe 6 (2000) 313-323
25. Joukhadar C., and Muller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 44 (2005) 895-913
26. Ballow C., Lettieri J., Agarwal V., Liu P., Stass H., and Sullivan J.T. Absolute bioavailability of moxifloxacin. Clin Ther 21 (1999) 513-522
27. Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. JAMA 297 (2007) 2466-2468